As conversation expands beyond amyloid, upcoming conference highlights shift toward neurotech, regenerative medicine and practical home care.
The Alzheimer’s Association International Conference (AAIC) has long been where the field reveals its next chapter. This year’s meeting, taking place 12–15 July in London, looks no different.
While headline-grabbing drug approvals have reshaped Alzheimer’s care over the past few years, AAIC 2026 suggests the conversation is beginning to widen. Alongside established pharmaceutical players, researchers are presenting new approaches ranging from wearable neurotechnology and regenerative medicine to therapies targeting distinct biological drivers of the disease.
That’s diversity. Alzheimer’s is increasingly understood as a complex disease rather than one with a single cause, meaning future care will likely rely on multiple strategies working together instead of one breakthrough alone.
Here are four companies drawing attention at AAIC 2026 and what their latest data could mean for the future of healthy brain aging.
Cognito Therapeutics: Can gentle brain stimulation strengthen resilience?
Rather than developing another drug, Cognito Therapeutics is betting on technology. The company will present new biomarker data on Spectris, an investigational, non-invasive device designed to stimulate the brain using synchronized light and sound while patients remain at home [1].
The latest findings suggest that the therapy increased levels of proteins involved in transporting cholesterol-like fats throughout the brain. While that may sound highly technical, these transport systems help support healthy brain cells and may contribute to the brain’s ability to cope with Alzheimer’s-related damage.
The results are still exploratory, but they offer another clue that brain stimulation could influence biology, not simply symptoms.
“We are encouraged to present additional biomarker data at AAIC 2026 that continue to deepen our understanding of the biological effects of Spectris therapy in Alzheimer’s disease,” said Christian Howell, CEO, Cognito Therapeutics. “Our focus remains on developing a non-invasive therapy that can be used at home and has the potential to fit more seamlessly into the daily lives of people living with Alzheimer’s.”
If future studies confirm these findings, therapies like Spectris could become part of a broader toolkit that supports brain resilience without adding to the treatment burden many older adults already face.
Biogen: Looking beyond amyloid
Biogen arrives at AAIC with one of the conference’s largest Alzheimer’s programs, but this year the spotlight extends beyond its already approved therapy, LEQEMBI.
The company will present Phase 2 data for diranersen, an investigational therapy designed to reduce tau, a protein that accumulates inside brain cells as Alzheimer’s progresses. While amyloid has dominated drug development for years, many researchers now believe tackling tau may be equally important for slowing cognitive decline [2].
“Biogen remains committed to advancing innovation across Alzheimer’s care, from treatment delivery and real-world evidence generation to continued progress in addressing core pathologies, including amyloid and tau,” said Dr Priya Singhal, MPH, Executive Vice President and Head of Development at Biogen.
Beyond new experimental therapies, Biogen will also showcase real-world experience with LEQEMBI, including data on at-home injections, long-term maintenance treatment and how patients are managing therapy outside tightly controlled clinical trials.
Alzheimer’s innovation is no longer measured only by whether a treatment works in research settings, but also by how easily it can fit into everyday life.
Eisai: Building on real-world experience
As Biogen’s long-time collaborator on LEQEMBI, Eisai is bringing one of the largest scientific programs to AAIC, with more than 50 presentations spanning treatment, diagnosis and patient care. Much of the company’s focus moves beyond clinical trial results and into what happens after approval.
Researchers will present updated findings from the LEADER study, which follows people receiving LEQEMBI in routine clinical practice. Topics include once-monthly maintenance treatment, early experiences with at-home injections and patient-reported outcomes – all questions that become increasingly important as therapies transition into widespread use [3].
“We are sharing a broad and robust data set at AAIC spanning the Alzheimer’s disease continuum, multiple therapeutic targets and modes of administration, underscoring our commitment to advancing care for this complex disease,” said Dr Lynn D Kramer, FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL) at Eisai.
Eisai will also present research on blood-based biomarkers and therapies targeting tau, highlighting a broader strategy that combines earlier diagnosis with more personalized treatment choices.
Taken together, the presentations suggest the next challenge in Alzheimer’s care may not simply be discovering new medicines, but making existing ones more accessible, practical and tailored to individual patients.
Longeveron: Regenerative medicine enters the conversation
Stem cell therapies have often been discussed on the fringes of Alzheimer’s research. Longeveron hopes to bring them closer to the mainstream.
The company will present additional Phase 2a analyses for laromestrocel, its investigational stem cell therapy for mild Alzheimer’s disease. Earlier results from the CLEAR MIND study, published in Nature Medicine in 2025, supported continued clinical development, and the new AAIC presentation builds on those findings [4].
Unlike drugs that primarily target specific Alzheimer’s proteins, laromestrocel is intended to help create an environment that supports healthier brain tissue by reducing inflammation and promoting repair mechanisms.
Whether that approach ultimately changes disease progression remains to be proven, but it reflects a growing recognition that healthy aging depends not only on removing harmful proteins but also on helping the brain recover and remain resilient.
As regenerative medicine continues to mature, therapies like laromestrocel may expand the range of options available for age-related neurological disease.
A more diverse Alzheimer’s pipeline emerges
AAIC 2026 makes one trend increasingly difficult to ignore: Alzheimer’s innovation is becoming more diverse.
Drug developers continue to refine therapies aimed at amyloid and tau, but they are now sharing the stage with neurotechnology, regenerative medicine and practical innovations that make treatment easier to deliver at home.
For longevity, that evolution matters. Extending lifespan has limited value if brain health cannot keep pace. The growing variety of approaches on display at AAIC reflects a broader shift toward preserving cognitive function, independence and quality of life – goals that sit at the heart of healthy longevity.
Rather than searching for a single silver bullet, the future of Alzheimer’s care may lie in combining multiple strategies that help people live not only longer, but cognitively healthier lives.
[1] https://www.businesswire.com/news/home/20260622473406/en/Cognito-Therapeutics-to-Present-New-Data-Highlighting-Effects-of-Spectris-on-Lipid-Transport-Biomarkers-in-Alzheimers-Disease-at-AAIC-2026
[2] https://investors.biogen.com/news-releases/news-release-details/biogen-highlight-breadth-alzheimers-disease-portfolio-aaic-2026
[3] https://www.eisai.com/news/2026/pdf/enews202635pdf.pdf
[4] https://investors.longeveron.com/news/News/news-details/2026/New-Phase-2a-Clinical-Data-Analysis-of-Stem-Cell-Therapy-Laromestrocel-in-Mild-Alzheimers-Disease-Accepted-for-Poster-Presentation-at-the-2026-Alzheimers-Association-International-Conference-AAIC/default.aspx
